Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 10;15(1):3947.
doi: 10.1038/s41467-024-48296-z.

Assessment of three antibiotic combination regimens against Gram-negative bacteria causing neonatal sepsis in low- and middle-income countries

Affiliations

Assessment of three antibiotic combination regimens against Gram-negative bacteria causing neonatal sepsis in low- and middle-income countries

Biljana Kakaraskoska Boceska et al. Nat Commun. .

Abstract

Gram-negative bacteria (GNB) are a major cause of neonatal sepsis in low- and middle-income countries (LMICs). Although the World Health Organization (WHO) reports that over 80% of these sepsis deaths could be prevented through improved treatment, the efficacy of the currently recommended first- and second-line treatment regimens for this condition is increasingly affected by high rates of drug resistance. Here we assess three well known antibiotics, fosfomycin, flomoxef and amikacin, in combination as potential antibiotic treatment regimens by investigating the drug resistance and genetic profiles of commonly isolated GNB causing neonatal sepsis in LMICs. The five most prevalent bacterial isolates in the NeoOBS study (NCT03721302) are Klebsiella pneumoniae, Acinetobacter baumannii, E. coli, Serratia marcescens and Enterobacter cloacae complex. Among these isolates, high levels of ESBL and carbapenemase encoding genes are detected along with resistance to ampicillin, gentamicin and cefotaxime, the current WHO recommended empiric regimens. The three new combinations show excellent in vitro activity against ESBL-producing K. pneumoniae and E. coli isolates. Our data should further inform and support the clinical evaluation of these three antibiotic combinations for the treatment of neonatal sepsis in areas with high rates of multidrug-resistant Gram-negative bacteria.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following competing interests: J.A.B.: Research grant support to the university from Wellcome, NIHR, MRC, and the Bill & Melinda Gates Foundation who had no role in any aspect of the study or decision to publish. A.S.W. is an NIHR Senior Investigator supported by the NIHR Biomedical Research Center Oxford and core support to the MRC Clinical Trials Unit [MC_UU_00004/05]. J.B. is an NIHR Advanced Fellow and Chief Investigator supported by grant NIHR302554 and H2020 Agreement number 965328. The remaining authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Distribution of the total number (indicated next to the bars) of the five most common GNB species analyzed by site.
n = 309, one isolate per species per patient only, following removal of duplicates. Number of isolates correlates with the number of neonates, except for the following sites: TH13 (13 neonates–14 isolates), SA12 (46 neonates–51 isolates), SA11 (51 neonates–56 isolates), SA10 (75 neonates–77 isolates) and BR2 (5 neonates–6 isolates).* VI Vietnam, UG Uganda, TH Thailand, SA South Africa, KE Kenya, IT Italy, GR Greece, BR Brazil, BA Bangladesh. The numbers following the country keys refer to the site number (see Table 1). Source data are provided as a Source Data file.
Fig. 2
Fig. 2. Minimum spanning tree of cgMLST analysis of MDR clones of K. pneumoniae (n = 79) showing specific local site clustering.
STs with three or more isolates are presented. A ST based clustering. B Site based clustering. VI Vietnam, UG Uganda, TH Thailand, SA South Africa, KE Kenya, GR Greece, BR Brazil, BA Bangladesh. The numbers following the country keys refer to the site number. Source data are provided as a Source Data file.
Fig. 3
Fig. 3. Distribution of ESBL genes of K. pneumoniae isolates (n = 135) by site.
(n) = total number of K. pneumoniae isolates per site. *VI Vietnam, UG Uganda, TH Thailand, SA South Africa, KE Kenya, IT Italy, BR Brazil, BA Bangladesh. The numbers following the country keys refer to the site number. Source data are provided as a Source Data file.
Fig. 4
Fig. 4. Distribution of carbapenem resistance genes of K. pneumoniae isolates (n = 135) by site.
(n) = total number of K. pneumoniae isolates per site. Sites that collected K. pneumoniae isolates lacking any carbapenem resistance genes are not shown in this figure (UG15 n = 5, GR4 n = 4, KE9 n = 4, IT8 n = 3, BR3 n = 3 and TH14 n = 2). *VI Vietnam, UG Uganda, TH Thailand, SA South Africa, KE Kenya, IT Italy, GR Greece, BR Brazil, BA Bangladesh. The numbers following the country keys refer to the site number. Source data are provided as a Source Data file.
Fig. 5
Fig. 5. Minimum spanning tree from A. baumannii genomes (n = 80) by cgMLST sequence types (STs).
A ST based clustering. B Site based clustering. VI Vietnam, UG Uganda, TH Thailand, SA South Africa, KE Kenya, BA Bangladesh. The numbers following the country keys refer to the site number. Source data are provided as a Source Data file.
Fig. 6
Fig. 6. Distribution of carbapenem resistance genes in A. baumannii isolates (n = 80) by site.
Site UG15 (n = 1) not represented in the chart since one unique A. baumannii isolate lacking any acquired carbapenemase producing genes. *VI Vietnam, UG Uganda, TH Thailand, SA South Africa, KE Kenya, IT Italy, GR Greece, BR Brazil, BA Bangladesh. The numbers following the country keys refer to the site number. Source data are provided as a Source Data file.
Fig. 7
Fig. 7. Isolates flow diagram.
The flow diagram provides an overview of the total number of isolates received at the laboratory of the University of Antwerp during the NeoOBS study and subsequent selection to the final number of isolates included in this study. GNB gram-negative bacteria, GPB gram-positive bacteria, MIC minimum inhibitory concentration.

References

    1. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet399, 629–655 (2022). - PMC - PubMed
    1. World Health Organization. Global report on the epidemiology and burden of sepsis: current evidence, identifying gaps and future directions. https://www.who.int/publications/i/item/9789240010789. (2020) (Last access date November 1, 2023).
    1. Gan MY, et al. Contemporary trends in global mortality of sepsis among young infants less than 90 days: a systematic review and meta-analysis. Front. Pediatr. 2022;10:890767. doi: 10.3389/fped.2022.890767. - DOI - PMC - PubMed
    1. Sands K, et al. Characterization of antimicrobial-resistant Gram-negative bacteria that cause neonatal sepsis in seven low- and middle-income countries. Nat. Microbiol. 2021;6:512–523. doi: 10.1038/s41564-021-00870-7. - DOI - PMC - PubMed
    1. Investigators of the Delhi Neonatal Infection Study (DeNIS) collaboration Characterisation and antimicrobial resistance of sepsis pathogens in neonates born in tertiary care centres in Delhi, India: a cohort study. Lancet Glob. Health. 2016;4:e752–e760. doi: 10.1016/S2214-109X(16)30148-6. - DOI - PubMed

Publication types

MeSH terms